Atterx Biotherapeutics
Madison
About Atterx Biotherapeutics
Atterx is developing fundamentally new therapeutics to combat the growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon's core technology is a new way to kill unwanted and even multi-drug resistant bacteria. The company is located in the MG&E Innovation Center in the University Research Park in Madison, Wisconsin.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $6.2M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2023)
- Website: atterx.com
- Phone: 6084412891
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/atterx-biotherapeutics-136301 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.